Cargando…

Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses

PURPOSE: Several options are available for the treatment of hypertension; however, many treated patients are still not below blood pressure (BP) target. Eplerenone, a selective mineralocorticoid receptor antagonist, is an approved treatment option for the management of patients with hypertension in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernet, Mireille, Beckerman, Bruce, Abreu, Paula, Lins, Katharina, Vincent, John, Burgess, Ellen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157540/ https://www.ncbi.nlm.nih.gov/pubmed/30275698 http://dx.doi.org/10.2147/VHRM.S170141

Ejemplares similares

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
por: Pereira, Sofia S., et al.
Publicado: (2021)

The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury
por: Jaisser, Frédéric, et al.
Publicado: (2021)

The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity
por: Nielsen, Finn Thomsen, et al.
Publicado: (2013)

Efficacy of mineralocorticoid receptor antagonism in the acute myocardial infarction phase: eplerenone versus spironolactone
por: Fraccarollo, Daniela, et al.
Publicado: (2015)

Synthesis and Physicochemical Characterization of the Process-Related Impurities of Eplerenone, an Antihypertensive Drug
por: Dams, Iwona, et al.
Publicado: (2017)

Mineralocorticoid Receptor Pathway Is a Key Mediator of Carfilzomib-induced Nephrotoxicity: Preventive Role of Eplerenone
por: Efentakis, Panagiotis, et al.
Publicado: (2022)

Safety and Antihypertensive Effect of Selara® (Eplerenone): Results from a Postmarketing Surveillance in Japan
por: Takahashi, Shoko, et al.
Publicado: (2016)

Why are mineralocorticoid receptor antagonists cardioprotective?
por: Chai, Wenxia, et al.
Publicado: (2006)

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
por: Yugar-Toledo, Juan Carlos, et al.
Publicado: (2017)

A combined CaMKII inhibition and mineralocorticoid receptor antagonism via eplerenone inhibits functional deterioration in chronic pressure overloaded mice
por: Driessen, Helen E., et al.
Publicado: (2020)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

Eplerenone ethanol solvate
por: Yang, Qian, et al.
Publicado: (2008)

The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic  Nephropathy
por: Goenka, Luxitaa, et al.
Publicado: (2019)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2021)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Vodošek Hojs, Nina, et al.
Publicado: (2021)

Mineralocorticoid receptor antagonists in cardiovascular translational biology
por: Chilton, Robert J., et al.
Publicado: (2023)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists
por: Mende, Christian W., et al.
Publicado: (2023)

Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
por: Funder, John W
Publicado: (2013)

Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy
por: Chin, Eric K, et al.
Publicado: (2015)

Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy
por: Sun, Li‐Jing, et al.
Publicado: (2017)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
por: Baran, Wiktoria, et al.
Publicado: (2021)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Adrenal gland inclusions in patients treated with aldosterone antagonists (Spironolactone/Eplerenone): incidence, morphology, and ultrastructural findings
por: Patel, Kishan A, et al.
Publicado: (2014)

Effects of mineralocorticoid receptor antagonists on responses to hemorrhagic shock in rats
por: Yamamoto, Kanako, et al.
Publicado: (2018)

Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
por: Kapoor, Kapil G., et al.
Publicado: (2016)

Mineralocorticoid receptor antagonist use following heart failure hospitalization
por: Duran, Jason M., et al.
Publicado: (2020)

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
por: Tezuka, Yuta, et al.
Publicado: (2021)

Quality of Life of Primary Aldosteronism Patients by Mineralocorticoid Receptor Antagonists
por: Yoshida, Yuichi, et al.
Publicado: (2021)

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
por: Agarwal, Rajiv, et al.
Publicado: (2020)

Novel 1,4-Dihydropyridine Derivatives as Mineralocorticoid Receptor Antagonists
por: Pérez-Gordillo, Felipe Luis, et al.
Publicado: (2023)

Eplerenone in the Treatment of Polypoidal Choroidal Vasculopathy
por: Kapoor, Kapil G., et al.
Publicado: (2015)

Eplerenone: The Multifaceted Drug in Cardiovascular Pharmacology
por: Pradhan, Akshyaya, et al.
Publicado: (2020)

Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!
por: Maiolino, Giuseppe, et al.
Publicado: (2015)

Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis
por: Berbenetz, Nicolas M., et al.
Publicado: (2016)

Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives
por: Vizzardi, Enrico, et al.
Publicado: (2014)

SAT-561 Effects of Mineralocorticoid Receptor Antagonists on Primary Aldosteronism Screening
por: Tezuka, Yuta, et al.
Publicado: (2020)

Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction
por: Chang, Wei-Ting, et al.
Publicado: (2022)

Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
por: Palanisamy, Srikanth, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p55be486kaqler0cmfeiuds0qb